Minophagen, Eisai deal

Eisai granted Minophagen exclusive rights to develop and commercialize Targretin bexarotene to treat cutaneous T cell lymphoma (CTCL) in 41 countries in Asia, Oceania, the Middle East and Eastern Europe. The countries include China, India, Korea, Taiwan, Australia, Saudi Arabia and Russia. Eisai will receive an upfront payment and is eligible for milestones, plus royalties. The pharma retains the right of first negotiation to co-commercialize the product in the territories. Details were not disclosed. Last year, Eisai granted Minophagen rights to Targretin in Japan (see BioCentury, April 11, 2011). ...